Monomethyl auristatin E (CAT#: ADC-P-022)

A: MMAE is a potent cytotoxic agent commonly used in antibody-drug conjugates (ADCs) for targeted cancer therapies. It disrupts microtubule formation, leading to cell cycle arrest and apoptosis.

A: MMAE binds to tubulin and prevents microtubule polymerization, causing mitotic arrest. When conjugated to antibodies, it is selectively delivered to cancer cells, minimizing systemic toxicity.

A: MMAE-based ADCs have been investigated in various cancers, including lymphoma, breast cancer, and non-small cell lung cancer, showing significant promise in preclinical and clinical studies.

A: In ADCs, MMAE is conjugated to an antibody via a cleavable linker. The antibody targets specific tumor antigens, and upon internalization, MMAE is released to exert its cytotoxic effects.

A: Creative Biolabs provides custom ADC development services, including MMAE conjugation, to tailor ADCs to specific research needs, enabling efficient exploration of novel cancer therapies.